542 related articles for article (PubMed ID: 35907493)
21. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
22. Progress of research on PD-1/PD-L1 in leukemia.
Cao H; Wu T; Zhou X; Xie S; Sun H; Sun Y; Li Y
Front Immunol; 2023; 14():1265299. PubMed ID: 37822924
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
25. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
26. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.
AmeliMojarad M; AmeliMojarad M; Cui X
Pathol Res Pract; 2023 Apr; 244():154338. PubMed ID: 36905697
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers that may predict response to immunotherapy in ovarian malignancies.
Chin CD; Fares CM; Konecny GE; Rao J
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):84-90. PubMed ID: 31804230
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
29. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.
Pawłowska A; Suszczyk D; Okła K; Barczyński B; Kotarski J; Wertel I
Clin Exp Immunol; 2019 Mar; 195(3):334-344. PubMed ID: 30582756
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
32. New advances in the treatment of chondrosarcoma under the PD-1/PD-L1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract][Full Text] [Related]
33. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.
Zhang Q; Yang C; Gao X; Dong J; Zhong C
Phytother Res; 2024 Feb; 38(2):776-796. PubMed ID: 38050789
[TBL] [Abstract][Full Text] [Related]
34. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.
Tang Q; Chen Y; Li X; Long S; Shi Y; Yu Y; Wu W; Han L; Wang S
Front Immunol; 2022; 13():964442. PubMed ID: 36177034
[TBL] [Abstract][Full Text] [Related]
35. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
[TBL] [Abstract][Full Text] [Related]
36. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
37. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities.
Peng Z; Li M; Li H; Gao Q
Drug Discov Today; 2023 Aug; 28(8):103666. PubMed ID: 37302543
[TBL] [Abstract][Full Text] [Related]
38. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
39. Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.
Zhang Y; Cui Q; Xu M; Liu D; Yao S; Chen M
Front Immunol; 2022; 13():901772. PubMed ID: 35833132
[TBL] [Abstract][Full Text] [Related]
40. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]